Monoamine oxidase B (MAO B) plays a pivotal role in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced Parkinsonism Since unequivocal data on platelet MAO B activity in PD patients cannot be drawn from these studies and because of its importance in MPTP-induced nigrostriatal neural degeneration, we studied platelet MAO B activity in a group of PD patients.
Human blood platelets may be regarded as a reliable model of monoaminergic synaptosome because of their specific biochemical mechanisms for uptake, storage, metabolism and release of several amines.' Platelets and nerve cells both have monoamine oxidase B (MAO B),2 which inhibits arylalkylamine dependent serotonin (5HT) release in platelets, thus enhancing its storage.3 Basing their investigation on different substrate affinity, Zeller et al' reported a qualitative difference in platelet MAO B activity between PD patients and controls, but Mann et al' noticed no change. Moreover, Danielczyc et al' reported platelet MAO B activity in PD patients treated with levodopabenserazide and amantadine which was higher than in controls; the effect of the combination of these drugs, however, on MAO B activity is not completely known. Recently it has been suggested that platelet MAO B activity may be a good peripheral marker to evaluate the time course of 1-deprenyl MAO B inhibitory action in PD,7 but the study in question was unfortunately not concerned with the possible differences in platelet MAO activity between PD patients and normal controls.
MAO Male patients showed a mean (SD) activity of 37-77 (15-77) nmol/mg prot/h, significantly higher (p < 0-001) than that of male controls, 25-58 (3-99). For female subjects, the mean value in patients was 46-90 (11 72) nmol/mg prot/h, significantly greater (p < 0-001) than the control mean 29-50 (2 04). We observed no significant differences between male and female MAO activity in PD group or in the control group.
No correlation was found between platelet enzyme activity and severity or length of illness. 
